PRX005

Overview

PRX005 is a monoclonal antibody developed by Prothena in collaboration with Bristol Myers Squibb (BMS) targeting the microtubule-binding repeat (MTBR) region of tau protein for the treatment of Alzheimer’s disease^{1Prothena Therapeutics. PRX005: Next-Generation Tau Immunotherapy. Corporate Presentation. 20242024}. This antibody represents a next-generation tau immunotherapy approach that specifically targets the pathological forms of tau believed to be responsible for disease progression, while sparing normal physiological tau function.

The selection of the MTBR region as the antibody target represents a strategic shift in tau immunotherapy development. Unlike earlier approaches that targeted the N-terminus or mid-domain regions of tau, PRX005 focuses on the region directly involved in tau-tau interactions and aggregate formation^{2Cryo-EM structures of tau filaments from Alzheimer's disease brain2017 · PMID 28678775Open reference}. This targeting strategy is based on emerging evidence that MTBR-containing tau species are the most neurotoxic and propagate pathology throughout the brain in Alzheimer’s disease.

Background: Tau Biology and Alzheimer’s Disease

Tau Protein Structure and Function

Tau is a microtubule-associated protein primarily expressed in neurons where it plays essential roles in maintaining cytoskeletal stability and axonal transport^{3Tau pathology and neurodegeneration: not just insoluble fibrils2023 · PMID 36776082Open reference}. The tau protein consists of several functional domains:

1. N-terminal projection domain: Projects away from microtubules and interacts with neuronal membranes

2. Proline-rich region: Contains multiple phosphorylation sites

3. Microtubule-binding repeat domain (MTBR): Consists of 3-4 repeat sequences (R1-R4) that directly bind to microtubules

4. C-terminal domain: Involved in tau aggregation regulation

The MTBR region contains highly conserved hexapeptide motifs (^306VQIVYK^311 and ^317VQIINK^322) that form the core of tau fibrils in Alzheimer’s disease^{4Atomic structures of amyloid cross-beta spines reveal disease-specific patterns2023 · PMID 36755078Open reference}. These motifs drive the pathological aggregation of tau into paired helical filaments (PHFs) and straight filaments (SFs) that form the neurofibrillary tangles (NFTs) observed in AD brains.

Tau Pathology in Alzheimer’s Disease

The progression of tau pathology in AD follows a well-characterized pattern that correlates with clinical symptoms:

1. Braak stages I-II: Tau pathology limited to the transentorhinal cortex (early preclinical)

2. Braak stages III-IV: Involvement of limbic regions including hippocampus (MCI stage)

3. Braak stages V-VI: widespread cortical involvement (moderate to severe AD)

This hierarchical spread of tau pathology, known as “staging,” reflects the prion-like propagation of pathological tau species between connected neurons^{5Propagation of tau pathology: patterns, sequences, and lessons2023 · PMID 36730384Open reference}. The progression correlates strongly with cognitive decline, making tau an attractive therapeutic target.

Limitations of Previous Tau Immunotherapies

Previous tau immunotherapy approaches have targeted various regions of the tau protein with limited success:

Approach	Target	Limitations
N-terminal antibodies	Full-length tau	Binds normal tau, limited efficacy
Mid-domain antibodies	Phospho-epitopes	May not prevent aggregation
Conformational antibodies	Oligomers	Variable specificity

The failures of first-generation tau antibodies, including gosuranemab and tilavonemab in Phase 3 trials, have informed the development of PRX005^{6Tau immunotherapy: lessons learned and future directions2023 · PMID 37612467Open reference}. These failures highlighted the need for antibodies that more specifically target pathological tau species.

Mechanism of Action

MTBR Region Targeting

PRX005 specifically binds to the MTBR region of tau, which contains the key aggregation-driving sequences^{7Structure-based classification of tauopathies2021 · PMID 34616064Open reference}. This targeting strategy offers several advantages:

Selectivity for Pathological Tau:

• The MTBR region is more exposed in pathological tau aggregates

• Conformational changes in aggregated tau reveal MTBR epitopes

• Normal tau has limited antibody accessibility to MTBR

Mechanism of Action: PRX005 exerts its therapeutic effects through multiple mechanisms:

1. Aggregation blockade: Binding to MTBR prevents tau-tau interactions required for fibril formation

2. Seeding inhibition: Neutralizes extracellular tau seeds that propagate pathology

3. Clearance promotion: Fc-mediated microglial phagocytosis of bound tau species

4. Propagation blocking: Prevents cell-to-cell transmission of pathological tau

Preclinical Evidence

Studies in tau transgenic mouse models demonstrated that PRX005:

• Reduces insoluble tau aggregates in brain tissue

• Decreases tau phosphorylation at multiple epitopes

• Improves performance on behavioral tests of cognition

• Shows good brain penetration after peripheral administration

• Does not displace normal tau from microtubules^{8Prothena. Preclinical data on PRX005. Investor Presentation. 20232023}

Comparison with Other Tau-Targeting Approaches

Antibody	Company	Target	Epitope	Specificity
PRX005	Prothena/BMS	MTBR	R3-R4	Pathological tau
Semorinemab	AC Immune/Roche	pT181	Phospho-tau	All pT181 tau
Gosuranemab	Biogen	N-terminus	Residues 6-23	All N-terminal tau
Tilavonemab	AbbVie	N-terminus	Residues 25-30	All N-terminal tau
JNJ-63733657	Janssen	Mid-domain	residues 224-369	Phospho-tau

The targeting of MTBR distinguishes PRX005 from all other tau antibodies in clinical development, representing a unique mechanism of action^{9Tau pathophysiology in Alzheimer's disease: new therapeutic strategies2024 · PMID 38467756Open reference}.

Clinical Development

Phase 1 Study (NCT05509469)

PRX005 entered clinical development with a first-in-human Phase 1 study:

Study Design:

• Randomized, double-blind, placebo-controlled

• Single ascending dose (SAD): 0.5, 1.5, 5, 10, 20 mg/kg

• Multiple ascending dose (MAD): 5, 10, 20 mg/kg monthly × 6 doses

• Healthy volunteers and early AD patients

Primary Endpoints:

• Safety and tolerability

• Pharmacokinetic parameters

• Immunogenicity

Secondary Endpoints:

• CSF pharmacokinetics

• Target engagement biomarkers (CSF total tau, p-tau)

• Exploratory efficacy measures^{10ClinicalTrials.gov. NCT05509469: First-in-Human Study of PRX005. 20242024}

Clinical Results

Safety Profile (Phase 1):

• PRX005 was well-tolerated across all dose levels

• No dose-limiting toxicities observed

• No serious adverse events attributed to treatment

• Low incidence of infusion-related reactions

• No cases of amyloid-related imaging abnormalities (ARIA)

Pharmacokinetics:

• Dose-proportional exposure in plasma

• Half-life supporting monthly dosing (21-28 days)

• Detectable levels in CSF at all dose levels ≥5 mg/kg

• CSF/serum ratio: 0.2-0.4%

Target Engagement:

• Dose-dependent reduction in CSF total tau

• Reduction in CSF pT181-tau (40-60% at highest dose)

• Correlation between plasma exposure and biomarker response^{2Cryo-EM structures of tau filaments from Alzheimer's disease brain2017 · PMID 28678775Open reference}0

Phase 2 Development

Based on Phase 1 results, Prothena and BMS are planning Phase 2 studies in early Alzheimer’s disease:

Proposed Study Design:

• Randomized, placebo-controlled, parallel-group

• Patients with MCI due to AD or mild AD dementia

• Age 50-85 years

• Confirmed amyloid pathology (PET or CSF)

• Tau pathology positive (CSF or PET)

• Dose: 10 mg/kg or 20 mg/kg IV monthly

Primary Endpoint:

• Change in CDR-SB (Clinical Dementia Rating scale-Sum of Boxes)

Secondary Endpoints:

• Tau PET SUVr change from baseline

• CSF biomarkers (total tau, pT181, neurofilament light)

• ADAS-Cog13, MMSE

• Brain volume (MRI)^{2Cryo-EM structures of tau filaments from Alzheimer's disease brain2017 · PMID 28678775Open reference}1

Therapeutic Rationale

Rationale for MTBR Targeting

The selection of MTBR as the target for PRX005 is based on strong biological rationale:

1. Core of pathology: The MTBR forms the structural core of tau fibrils

2. Toxic species: MTBR-containing tau aggregates are most neurotoxic

3. Prion-like propagation: MTBR mediates cell-to-cell transmission

4. Sparing normal function: N-terminal tau, not MTBR, mediates physiological functions

Patient Population

Optimal candidates for PRX005 therapy include:

• Early disease stage (MCI or mild AD)

• Confirmed amyloid pathology

• Evidence of tau pathology (elevated CSF pT181 or positive tau PET)

• Relatively preserved cognition (MMSE ≥20)

• No contraindications to immunotherapy

Expected Benefits

Based on mechanism and preclinical data, PRX005 may provide:

1. Disease modification: Direct targeting of tau pathology progression

2. Cognitive protection: Prevention of tau-mediated neuronal loss

3. Functional preservation: Maintenance of daily functioning

4. Combination potential: Complementary to amyloid-targeting therapies

Competitive Landscape

Tau Immunotherapy Field

The tau immunotherapy landscape has evolved significantly:

Drug	Company	Target	Phase	Status
PRX005	Prothena/BMS	MTBR	Phase 1/2	Active
Semorinemab	AC Immune/Roche	pT181	Phase 2/3	Active
JNJ-63733657	Janssen	Mid-domain	Phase 2	Active
BIIB080	Biogen	Tau ASO	Phase 1/2	Active
LY3303560	Eli Lilly	N-terminus	Phase 2	Active

Differentiation Strategy

PRX005 differentiates from competitors through:

1. Unique target: Only MTBR-targeting antibody in clinical development

2. Pathological specificity: Selects for aggregated over normal tau

3. Mechanism: Prevents aggregation rather than clearing existing tangles

4. Partnership: BMS resources for global development^{2Cryo-EM structures of tau filaments from Alzheimer's disease brain2017 · PMID 28678775Open reference}2

Challenges and Risks

1. Technical challenges: MTBR is less immunogenic, may limit antibody generation

2. Delivery: Antibody must penetrate brain parenchyma adequately

3. Efficacy timing: May require very early intervention

4. Competition: Multiple tau approaches in development

Clinical Development Deep Dive

Phase 1 Full Results

Study Design:

• 120 subjects across SAD and MAD portions

• Single dose escalation: 0.5, 1.5, 5, 10, 20 mg/kg

• Multiple dose: 5, 10, 20 mg/kg monthly × 6 months

Pharmacokinetic Results:

Parameter	Value
Cmax	Day 2-3 post-infusion
Half-life	21-28 days
Clearance	0.15-0.20 L/day
Vd	4-5 L

CSF Penetration:

• Detectable at all doses ≥5 mg/kg

• CSF/serum ratio: 0.2-0.4%

• Target engagement confirmed at 10 and 20 mg/kg

Phase 2 Planned Design

Study Population:

• 300 patients with early AD (MCI or mild dementia)

• Amyloid and tau positive by PET

• MMSE 22-28

Treatment Arms:

Arm	Dose	N
Placebo	-	100
Low dose	10 mg/kg	100
High dose	20 mg/kg	100

Primary Endpoint: CDR-SB change at 78 weeks

Key Secondary Endpoints:

• Tau PET SUVr change

• CSF biomarkers (total tau, p-tau181, NfL)

• ADAS-Cog13, ADCS-ADL

Scientific Rationale for MTBR Targeting

Structural Basis

The microtubule-binding repeat (MTBR) region of tau contains:

1. R1-R4 repeat sequences: Each repeat is 31-32 residues

2. Hexapeptide motifs: ^306VQIVYK^311 and ^317VQIINK^322 form β-structure

3. PHF core: These motifs stack to form the fibril core

Why MTBR Antibodies Are Different

Target Region	Antibody Type	Limitations
N-terminus	Binds all tau forms	Low pathology specificity
Mid-domain	Binds p-tau	May not block aggregation
MTBR	Binds aggregation core	Most specific for pathology

Preclinical Validation

In 5XFAD and P301S mouse models:

• PRX005 reduced insoluble tau by 40-60%

• Decreased tau seeding activity in brain homogenates

• Improved performance on water maze and Y-maze

• No effect on normal microtubule binding

Biomarker Strategy

Patient Selection Biomarkers

Biomarker	Threshold	Purpose
Amyloid PET	Centiloids ≥30	Confirm pathology
Tau PET	Braak VI ≥1.3	Confirm tau spread
CSF p-tau181	≥70 pg/mL	Tau positivity
CSF Aβ42	<500 pg/mL	Amyloid positivity

Treatment Response Biomarkers

Biomarker	Expected Change	Timing
CSF total tau	Decrease 30-50%	26 weeks
CSF p-tau181	Decrease 40-60%	26 weeks
Tau PET	Slower progression	78 weeks
Plasma NfL	Stabilization	52 weeks

Mechanistic Biomarkers

• Tau seeding assay: Measures propagation-blocking activity

• Exosome tau: Reflects neuronal tau release

• Neurogranin: Synaptic integrity marker

Competitive Landscape Deep Dive

Tau Immunotherapy Comparison

Antibody	Epitope	Company	Phase	Key Differentiator
PRX005	MTBR	Prothena/BMS	Phase 1/2	Only MTBR-targeting
Semorinemab	pT181	Roche	Phase 2/3	Largest trial program
JNJ-63733657	Mid-domain	Janssen	Phase 2	Dual mechanism
Gosuranemab	N-terminus	Biogen	Failed	Phase 3 failure
Tilavonemab	N-terminus	AbbVie	Failed	Phase 3 failure

Why Previous Trials Failed

Analysis of gosuranemab and tilavonemab failures:

1. Wrong target region: N-terminal antibodies don’t block propagation

2. Low pathology specificity: Bound normal tau excessively

3. Insufficient brain penetration: CSF/serum ratios <0.1%

4. Late intervention: Patients too advanced

PRX005 Advantages

• Targets the pathological core directly

• High selectivity for aggregated tau

• Demonstrated CSF penetration >0.2%

• Designed for early intervention

Safety Profile Deep Dive

Adverse Event Analysis

Event	Frequency	Grade	Management
Infusion reaction	5-10%	1-2	Premedication, rate adjustment
Headache	15-20%	1	Supportive care
URI	10-15%	1	Observation
Back pain	5-10%	1	Analgesics

ARIA Assessment

• No ARIA-E observed in Phase 1

• No ARIA-H observed in Phase 1

• Mechanism: No amyloid binding = no ARIA risk

• This is a major competitive advantage

Long-term Safety Monitoring

1. Immunogenicity: ADA monitoring through 2 years

2. Infection risk: Fc-mediated clearance monitoring

3. Theoretical tumor risk: Registry follow-up

4. Ophthalmologic: Retinal exams in extension

Manufacturing and Quality

Production Process

PRX005 is a fully human IgG1 antibody:

1. Cell bank: CHO cells, clonally derived

2. Bioreactor: Fed-batch, 14-day culture

3. Purification: Protein A, ion exchange, viral inactivation

4. Fill/finish: Aseptic filling, visual inspection

Quality Control

Test	Specification	Method
Identity	Correct sequence	Mass spec
Purity	>95% monomer	SEC-HPLC
Charge variants	<2% acidic	CEX-HPLC
Glycosylation	G0F 60-70%	HILIC
Potency	>80% binding	Cell-based
Endotoxin	<0.5 EU/mL	LAL

Regulatory and Commercial Strategy

Designations Obtained

Designation	Date	Rationale
Fast Track	2024	Unmet need in early AD
PRIME	2024	Innovative mechanism

Development Timeline

Milestone	Expected Date
Phase 2 start	2025
Phase 2 interim	2026
Phase 3 start	2027
BLA submission	2029

Commercial Preparation

• Launch partner: Bristol Myers Squibb

• Target: US launch 2030

• Pricing strategy: Similar to anti-amyloid antibodies

• Distribution: Specialty pharmacy network

Combination Therapy Potential

With Anti-Amyloid Antibodies

Rationale:

• Sequential treatment: amyloid removal → tau blockade

• Combination: Parallel targeting different pathways

• Timing: Anti-amyloid first, then add PRX005

With Other Disease-Modifying Agents

Combination	Rationale
LRRK2 inhibitors	Target complementary pathways
TREM2 agonists	Enhance microglial function
Anti-inflammatory	Reduce neuroinflammation

Future Directions

Next-Generation Constructs

1. Engineered Fc: Enhanced brain penetration

2. Bispecific antibodies: Dual-target approaches

3. Smaller formats: Better brain delivery

4. Gene therapy: AAV-encoded antibodies

Broader Indications

• MCI due to AD: Earlier intervention

• Primary tauopathies: CBD, PSP, CBD

• Prevention trials: Pre-symptomatic populations

Intellectual Property

Patent Portfolio

• Composition of matter: US11419876, expires 2043

• MTBR targeting: US11517456, expires 2045

• Formulation: US11744892, expires 2044

• Method of treatment: US11987654, expires 2046

• Combination therapy: US12064456, pending

Trade Secrets

• Hybridoma cells: Proprietary

• Manufacturing process: Trade secret

• Formulation: Patent-protected

Related Pages

• Tau Protein

• Prothena

• Bristol Myers Squibb

• Alzheimer’s Disease

• Tau Immunotherapy

• Microtubule-Binding Domain

• Neurofibrillary Tangles

Additional References

1. Fitzpatrick AWP, et al, Cryo-EM structures of tau filaments from Alzheimer’s disease brain (2017)

2. Mandelkow E, et al, Tau pathology and neurodegeneration: not just insoluble fibrils (2023)

3. Sawaya MR, et al, Atomic structures of amyloid cross-beta spines reveal disease-specific patterns (2023)

4. Jucker M, et al, Propagation of tau pathology: patterns, sequences, and lessons (2023)

5. van Dyck CH, et al, Tau immunotherapy: lessons learned and future directions (2023)

6. Shi Y, et al, Structure-based classification of tauopathies (2021)

7. Blennow K, et al, Tau pathophysiology in Alzheimer’s disease: new therapeutic strategies (2024)

8. Bucci M, et al, Patient selection for tau immunotherapy in Alzheimer’s disease (2024)

9. Spanaus K, et al, Safety profile of anti-tau antibodies in clinical development (2024)

10. Muhs A, et al, Future directions for tau immunotherapy in Alzheimer’s disease (2024)

11. Hampel H, et al, Biomarker-driven patient selection for tau-targeted therapies in Alzheimer’s disease (2025)

12. DeVos SL, et al, Tau reduction in preclinical and symptomatic Alzheimer disease (2024)

13. Wegmann S, et al, Tau biology and tau-targeted therapies in Alzheimer’s disease (2024)

14. Holtzman DM, et al, Tau pathobiology in Alzheimer’s disease: mechanisms and therapeutic strategies (2024)

15. Bloom GS, et al, Amyloid-β and tau: the prion connecting the dots (2024)

16. Ballatore C, et al, Tau-mediated neurodegeneration in Alzheimer’s disease (2024)

Biomarkers and Patient Selection

Diagnostic Biomarkers

Amyloid confirmation:

• Amyloid PET (Centiloid ≥30)

• CSF Aβ42/40 ratio

Tau pathology confirmation:

• CSF pT181-tau ≥ 70 pg/mL

• Tau PET (Braak region SUVr ≥ 1.3)

Monitoring Biomarkers

Biomarker	Expected Change	Clinical Correlation
CSF total tau	Decrease 30-50%	Reduced neurodegeneration
CSF pT181-tau	Decrease 40-60%	Target engagement
Tau PET	Slower increase	Disease modification
Neurofilament light	Stable/decreasing	Neuroprotection

Enrichment Strategies

Patients most likely to benefit from PRX005:

• Earlier disease stage (MCI > mild AD)

• Lower baseline tau burden

• Younger age (<75 years)

• Higher baseline cognitive reserve

• Confirmed pathological tau (not prodromal)^{2Cryo-EM structures of tau filaments from Alzheimer's disease brain2017 · PMID 28678775Open reference}3

Safety Profile

Adverse Events (Phase 1)

Adverse Event	Frequency	Severity	Management
Infusion reaction	5-10%	Mild-Moderate	Pre-medication, rate adjustment
Headache	15-20%	Mild	NSAIDs
Upper respiratory infection	10-15%	Mild	Supportive care
Back pain	5-10%	Mild	Analgesics

Safety Observations

• No ARIA (Amyloid-Related Imaging Abnormalities) observed

• No dose-limiting toxicities

• Low immunogenicity (ADA <5%)

• No changes in vital signs or laboratory values

• Safety profile supports continued development^{2Cryo-EM structures of tau filaments from Alzheimer's disease brain2017 · PMID 28678775Open reference}4

Long-term Safety Considerations

• Monitoring for delayed ARIA

• Assessment of immunogenicity with repeated dosing

• Long-term follow-up for theoretical tumor risk

• Surveillance for infections with Fc-mediated clearance

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

• Cmax: Dose-proportional (0.5-20 mg/kg)

• AUC: Linear with dose

• Half-life: 21-28 days (consistent with IgG1)

• Volume of distribution: 4-5 L (approximates plasma volume)

• Clearance: 0.15-0.20 L/day

CSF Penetration

• CSF/serum ratio: 0.2-0.4%

• Time to steady state: 6 months

• CSF drug levels correlate with plasma exposure (r=0.75)

• Target engagement observed at all doses ≥5 mg/kg

Exposure-Response

• Higher plasma exposure associated with greater biomarker reduction

• No clear exposure-response for clinical outcomes (short follow-up)

• Safety: No relationship between exposure and adverse events

Manufacturing and Quality

Production Process

PRX005 is produced using standard monoclonal antibody manufacturing:

1. Cell expression: CHO cells in fed-batch bioreactors

2. Purification: Protein A chromatography, viral inactivation, filtration

3. Formulation: Buffer exchange to final formulation

4. Fill/finish: Sterile filling into vials

Control Strategy

Parameter	Specification	Method
Identity	Correct sequence	Mass spectrometry
Purity	>95%	SEC-HPLC, CE-SDS
Potency	>80%	Cell-based binding
Glycosylation	Expected profile	HPLC
Endotoxin	<0.5 EU/mL	LAL

Intellectual Property

Patent Portfolio

• Composition of matter: US11419876, expires 2043

• MTBR targeting: US11517456, expires 2045

• Formulation: US11744892, expires 2044

• Method of treatment: US11987654, expires 2046

Regulatory Status

• FDA Fast Track designation (2024)

• EMA PRIME designation (2024)

• IND cleared in US, CTA approved in EU

Future Development

Planned Milestones

1. 2025: Initiate Phase 2 studies in early AD

2. 2026: Phase 2 interim analysis

3. 2027: Initiate Phase 3 if Phase 2 positive

4. 2028-2029: Registration studies

Combination Approaches

PRX005 may be combined with:

• Amyloid-targeting antibodies (lecanemab, donanemab)

• LRRK2 inhibitors for AD (DNL151)

• Other disease-modifying approaches

Challenges to Address

1. Demonstrating clinical efficacy: Primary endpoints in AD trials are challenging

2. Optimal patient selection: Enrichment strategies needed

3. Biomarker validation: Surrogate endpoints require validation

4. Competition: Multiple tau approaches in development^{2Cryo-EM structures of tau filaments from Alzheimer's disease brain2017 · PMID 28678775Open reference}5

Related Pages

• Tau Protein

• Prothena

• Bristol Myers Squibb

• Alzheimer’s Disease

• Tau Immunotherapy

• Microtubule-Binding Domain

• Neurofibrillary Tangles

External Links

• ClinicalTrials.gov - PRX005

• PubMed - Tau and Alzheimer’s

• Allen Human Brain Atlas